FDA acts against five medical practitioners

Nashik: The Food and Drugs’ Administration (FDA), Nashik division, has started taking action against unauthorized medical practitioners, who are carrying and prescribing allopathic medicine to the patients coming to them without having the requisite knowledge.
Last month, five such medical practitioners were identified in the district. While three are from Nandgaon taluka, one is from Nashik taluka and another is from Satpur area in Nashik city.

Joint director of FDA (drugs), Nashik, Madhuri Pawar said, “The report about the concerned medical practitioners has been sent to the district-level committee which will decide the future course of action.”

“These medical practitioners are unqualified but provide allopathy treatment to patients coming to them. Such people stock large quantities of allopathy medicines and treat patients, including giving injections. This is like playing with the lives of the patients. Hence, action was taken after receiving secret information from a civilian,” said Pawar.

Among these doctors, one had done a correspondence diploma course in herbal medicine and others had a diploma in electropathy alternative medicine and naturopathy. None of them had. the requisite qualifications of treating patients with allopathy medicines.

Pawar said the drugs department had also conducted a special drive in December under the Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954, in which raids were conducted at three places and medicine worth over Rs 12 lakh was seized.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’